Search

Search Results
Results 141 - 145 of 145 for Adr
  • Two Cents' Worth: Shared decision making in renal cell carcinoma (RCC)
    News - 15 Dec 2022
    In this interview, we speak to Steve Pointon, patient advocate in remission from RCC, and Dr Harm van Melick, Consultant Urologist, about their experiences with shared decision-making and the impact...
  • Preliminary results from Phase III study of afamelanotide in EPP announced
    News - 21 Dec 2009
    Clinuvel Pharmaceuticals Limited today announced that it has obtained promising 4-months results in testing afamelanotide in a multicentre randomised double-blind placebo controlled Phase III study in...
  • Why Pharmacovigilance Is More Critical Than Ever
    Life Sciences - 13 Nov 2025
    Pharmacovigilance evolves with technology, employing active surveillance to detect drug-related issues and ensure safety in an increasingly complex landscape.
  • What Happens When Drugs Fail Post-Approval?
    Life Sciences - 3 Apr 2025
    This article examines post-market drug safety, highlighting surveillance mechanisms, regulatory responses, and case studies of approved drugs with hidden risks.
  • Ipsen
    Supplier - 25 Nov 2022
    Ipsen’s vision is to be a leading global mid-size biopharmaceutical company with a focus on transformative medicines in three key therapeutic areas: oncology, rare disease, and neuroscience.

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback